	US 11,712,468 B2
	CD70 combination therapy
Johannes De Haard, Ghent (BE); Samson Fung, Ghent (BE); Nicolas Leupin, Ghent (BE); Adrian Ochsenbein, Ghent (BE); Carsten Riether, Ghent (BE); and Luc Van Rompaey, Ghent (BE)
Assigned to ARGENX BV, Ghent (BE); and University of Bern, Bern (CH)
Filed by Argenx BV, Ghent (BE); and University of Bern, Bern (CH)
Filed on Dec. 18, 2019, as Appl. No. 16/719,220.
Claims priority of application No. 1820582 (GB), filed on Dec. 18, 2018; application No. 1911007 (GB), filed on Aug. 1, 2019; and application No. 1917701 (GB), filed on Dec. 4, 2019.
Prior Publication US 2020/0222532 A1, Jul. 16, 2020
Int. Cl. A61K 39/395 (2006.01); A61K 31/496 (2006.01); A61K 31/706 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC A61K 39/3955 (2013.01) [A61K 31/496 (2013.01); A61K 31/706 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01)]

36 Claims

1. A method for treating a malignancy in a human subject, said method comprising administering to the subject an effective amount of a combination comprising

(i) an antibody or antigen binding fragment thereof that specifically binds to CD70, comprising a heavy chain variable domain (VH) comprising the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence of SEQ ID NO: 4 and a light chain variable domain (VL) comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence of SEQ ID NO: 8; wherein the antibody is not an antibody drug conjugate, and

(ii) venetoclax or a pharmaceutically acceptable salt thereof,

wherein the malignancy is selected from the group consisting of acute myeloid leukemia (AML); myelodysplastic syndromes (MDS); myeloproliferative neoplasms (MPN); chronic myeloid leukemia (CML); and chronic myelomonocytic leukemia (CMML).